Want to see NTHI full AI Analyst Report?
Top Page
NeOnc Technologies Holdings, Inc.
(NASDAQ:NTHI)
Select Model
Select Model
Rating:46Neutral
Price Target:
$4.00
▼(-15.43% Downside)
Action:Reiterated
Date:09/09/26
The score is held down primarily by extremely weak financial performance (near-zero revenue, very large losses, heavy cash burn, and negative equity implying high financing/dilution risk). Technicals are mixed—some positive momentum signals but the stock remains below longer-term moving averages. Corporate events add a modest positive offset due to encouraging Phase 2a data and regulatory progress, while valuation remains unfavorable given ongoing losses and no dividend support.
Positive Factors
Phase 2a clinical efficacy
The positive Phase 2a outcome provides clinical validation for NEO100 in recurrent high-grade glioma, where treatment options are limited. If confirmed in later studies and regulatory review, the result could support a registrational pathway, improve partnering potential, and establish a durable position in CNS oncology.
Negative Factors
Minimal commercial revenue
The company remains pre-commercial, with negligible revenue unable to offset its operating base. Very large losses relative to sales indicate that commercialization is still distant and that future progress depends primarily on clinical execution, regulatory success, and access to external capital rather than recurring business revenue.
Read all positive and negative factors
Positive Factors
Negative Factors
Phase 2a clinical efficacy
The positive Phase 2a outcome provides clinical validation for NEO100 in recurrent high-grade glioma, where treatment options are limited. If confirmed in later studies and regulatory review, the result could support a registrational pathway, improve partnering potential, and establish a durable position in CNS oncology.
Read all positive factors
NeOnc Technologies Holdings, Inc. (NTHI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$130.46M
Dividend YieldN/A
Average Volume (3M)220.73K
Price to Earnings (P/E)―
Beta (1Y)1.54
Revenue Growth-100.00%
EPS Growth18.94%
CountryUS
Employees5
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding25,936,365
10 Day Avg. Volume135,523
30 Day Avg. Volume220,727
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-9.07
Price to Sales (P/S)3973.02
P/FCF Ratio-7.62
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.00Price Target Upside322.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
NeOnc Technologies Holdings, Inc. Business Overview & Revenue Model
Company Description
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded ...
NeOnc Technologies Holdings, Inc. Financial Statement Overview
Summary
Income Statement
4
Very Negative
Balance Sheet
8
Very Negative
Cash Flow
6
Very Negative
| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 39.99K | 83.00K | 70.46K | 20.00K | 0.00 |
| Gross Profit | -57.52K | 39.99K | 83.00K | 70.46K | 20.00K | 0.00 |
| EBITDA | -43.63M | -59.61M | -9.10M | -12.20M | -2.85M | -3.26M |
| Net Income | -47.20M | -62.15M | -11.90M | -14.92M | -3.05M | -3.38M |
Balance Sheet | ||||||
| Total Assets | 5.23M | 2.82M | 3.42M | 1.27M | 728.68K | 32.49K |
| Cash, Cash Equivalents and Short-Term Investments | 1.97M | 58.73K | 64.89K | 31.86K | 633.30K | 25.03K |
| Total Debt | 328.22K | 6.31M | 24.72K | 6.61M | 50.00K | 1.15M |
| Total Liabilities | 23.76M | 20.33M | 8.92M | 15.25M | 2.30M | 2.65M |
| Stockholders Equity | -18.53M | -17.51M | -5.50M | -13.99M | -1.58M | -2.62M |
Cash Flow | ||||||
| Free Cash Flow | -21.16M | -20.86M | -4.21M | -1.88M | -881.74K | -396.69K |
| Operating Cash Flow | -21.16M | -20.36M | -4.21M | -1.88M | -881.74K | -396.69K |
| Investing Cash Flow | 0.00 | -500.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 23.51M | 20.86M | 4.25M | 1.28M | 1.49M | 250.00K |
NeOnc Technologies Holdings, Inc. Technical Analysis
Positive
4.73
Price Trends
8.91
Positive
9.12
Positive
Market Momentum
0.09
Negative
59.53
Neutral
61.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NTHI, the sentiment is Positive. The current price of 4.73 is below the 20-day moving average (MA) of 8.71, below the 50-day MA of 8.91, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of 0.09 indicates Negative momentum. The RSI at 59.53 is Neutral, neither overbought nor oversold. The STOCH value of 61.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NTHI.
NeOnc Technologies Holdings, Inc. Risk Analysis
NeOnc Technologies Holdings, Inc. disclosed 83 risk factors in its most recent earnings report. NeOnc Technologies Holdings, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NeOnc Technologies Holdings, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | $3.58M | -0.02 | -372.86% | ― | ― | 53.95% | |
46 Neutral | $130.46M | -1.83 | 309.09% | ― | -100.00% | 18.94% | |
41 Neutral | $4.39M | -0.03 | -743.66% | ― | -100.00% | 77.63% | |
40 Underperform | $271.78M | -0.05 | -443.08% | ― | ― | 75.09% |
* General Sector Average
NTHI
NeOnc Technologies Holdings, Inc.
4.07
-4.41
-52.00%
GOVX
GeoVax Labs
0.47
-16.76
-97.28%
GTBP
GT Biopharma
5.24
-13.45
-71.97%
CLDI
Calidi Biotherapeutics
1.35
-25.05
-94.89%
NeOnc Technologies Holdings, Inc. Corporate Events
Executive/Board ChangesShareholder Meetings
NeOnc Technologies Holds 2026 Annual Stockholder Meeting
Positive
Aug 20, 2026
NeOnc Technologies Holdings, Inc. held its 2026 annual meeting of stockholders via live webcast on August 14, 2026, with 77.92% of eligible common shares represented, establishing a quorum under its bylaws. Stockholders elected two Class I directo...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
NeOnc Announces Positive Phase 2a Data in Brain Cancer
Positive
Aug 13, 2026
On August 12, 2026, NeOnc Technologies hosted an investor conference call to present top-line Phase 2a results from its NEO100-01 trial in recurrent IDH1-mutant high-grade glioma, reporting that the study met its primary endpoint with a median ove...
Business Operations and Strategy
NeOnc Technologies Reports Positive Phase 2a Glioma Results
Positive
Aug 12, 2026
On August 12, 2026, NeOnc Technologies reported positive topline Phase 2a results from its NEO100-01 study of intranasal NEO100 in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma, a setting with no approved targete...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresRegulatory Filings and Compliance
NeOnc Highlights Q2 Results and CNS Oncology Progress
Neutral
Aug 10, 2026
NeOnc reported its second-quarter 2026 results on August 10, 2026, alongside clinical and regulatory milestones for its NEO100 and NEO212 programs, underscoring a strategic focus on advancing central nervous system cancer treatments. The company c...
Business Operations and StrategyExecutive/Board Changes
NeOnc Technologies Adds New Director Amid Governance Focus
Neutral
Jul 2, 2026
On June 27, 2026, NeOnc Technologies director Ming-Fu (Alan) Chiang resigned from the company’s Board of Directors and Scientific Advisory Board, with the company stating his departure did not stem from any dispute over operations, policies,...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
NeOnc Wins Abu Dhabi IND Clearance for NEO100
Positive
Jun 23, 2026
On June 23, 2026, NeOnc Technologies announced that Abu Dhabi’s Department of Health granted Investigational New Drug status for NEO100, its intranasally delivered perillyl alcohol formulation for nose-to-brain treatment of progressive or re...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
NeOnc Wins UAE IND Clearance for NEO212 Brain Therapy
Positive
Jun 18, 2026
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company specializing in central nervous system cancers, is advancing a pipeline centered on overcoming the blood-brain barrier, notably through its NEO100 and NEO212 candidates ...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
NeOnc Technologies Announces New Series A Preferred Financing
Positive
Jun 12, 2026
On June 10, 2026, NeOnc Technologies Holdings, Inc. entered into a Securities Purchase Agreement with accredited investors to privately place up to $5 million of Series A Convertible Preferred Stock, authorizing 6,000 shares at $833.34 each, exemp...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.